North. Unless AMRN gets some relief from the courts in the US ( reversal of judge Du's decision , restraining generic infringement etc ) ...the US market is going nowhere. Break even at best because AMRN will be very unlikely to spend $ expanding this market .
So that leaves the EU where we now have patent protection until 2039 ( from memory ) One approach to gain access to Germany , Italy and France is to engage those Health Depts in a short trial for a specific sub group where the economic benefits of risk reduction can easily be quantified.
Consider that " out to lunch " if you like but in the mean time what your ideas for gaining market share in these 3 key EU markets ...the same ol same ol ? Kiwi
News 
Market Data 
Discover 
